Abstract
A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to investigate the effect of replacement of chlorine with bromine or fluorine on the antitumor activity of the parent phosphoramide mustards. In the experimental tumors L1210 leukemia, B16 melanoma, mammary adenocarcinoma 16/C, and ovarian sarcoma M5076, the antitumor activity of the analogs was observed to be generally comparable with that of the parent mustards when chlorine was replaced by bromine but uniformly lower when chlorine was replaced by fluorine. Furthermore, the monobromo analog of isophosphoramide mustard displayed equal or somewhat greater activity in comparison with cyclophosphamide when evaluated against subcutaneously implanted L1210 leukemia with intraperitoneal drug treatment and against mammary adenocarcinoma 16/C.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brock N (1989) Oxazaphosphorine cytostatics: past-present-future. Cancer Res 49: 1
Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of nontoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 29: 659
Colvin M, Brundrett RB, kan M-NN, Jardine I, Fenselau C (1976) Alkylating properties of phosphoramide mustard. Cancer Res 36: 1121
Cox PJ (1979) Cyclophosphamide cystitis — identification of acrolein as the causative agent. Biochem Pharmacol 28: 2045
Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3: 2
Goren MP, Wright RK, Pratt CB (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet II: 1219
Lloyd HH (1977) Application of tumor models toward the design of treatment schedules for cancer chemotherapy: In: Drewinko B, Humphrey RM (eds) Growth kinetics and biochemical regulation of normal and malignant cells. Williams & Wilkins, Baltimore, p 455
Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH (1977) Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther [A] 1: 411
Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827
Skipper HE, Schabel FM, Wilcox WS, Laster WR, Trader MW, Thompson SA (1965) Experimental evaluation of potential anticancer agents. XVIII. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. Cancer Chemother Rep 47: 41
Sladek NE (1988) Metabolism of oxazaphosphorines. Pharmacol Ther 37: 301
Struck RF (1993) Synthesis and antitumor activity of halogen analogs of phosphoramide, isophosphoramide and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide and trofosfamide. Pharmacologist 35: 198
Struck RF, Kirk MC, Witt MH, Laster WR (1975) Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 2: 46
Zalupski M, Baker LH (1988) Ifosfamide. J Natl Cancer Inst 80: 556
Author information
Authors and Affiliations
Additional information
This work was financially supported by NIH, NCI grant PO1 CA34200
Rights and permissions
About this article
Cite this article
Struck, R.F., Schmid, S.M. & Waud, W.R. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide. Cancer Chemother. Pharmacol. 34, 191–196 (1994). https://doi.org/10.1007/BF00685076
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685076